Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.
This page provides an outline of the medicines and vaccines in development.
The content of our development pipeline will change over time as new compounds progress from discovery to development and from development to the market. This annual pipeline information was published in March 2016.
Owing to the nature of the drug development, many compounds - especially those in early stages of investigation - may be terminated through the development process. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.
Brand names are trademarks either owned by and/or licensed to GSK or associated companies.